A heterogenous group of disorders characterized by the abnormal increase of MAST CELLS in only the skin (MASTOCYTOSIS, CUTANEOUS), in extracutaneous tissues involving multiple organs (MASTOCYTOSIS, SYSTEMIC), or in solid tumors (MASTOCYTOMA).
A group of disorders caused by the abnormal proliferation of MAST CELLS in a variety of extracutaneous tissues including bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. Systemic mastocytosis is commonly seen in adults. These diseases are categorized on the basis of clinical features, pathologic findings, and prognosis.
Skin lesions due to abnormal infiltration of MAST CELLS. Cutaneous mastocytosis is confined to the skin without the involvement of other tissues or organs, and is mostly found in children. The three major variants are: URTICARIA PIGMENTOSA; diffuse cutaneous mastocytosis; and SOLITARY MASTOCYTOMA OF SKIN.
The most common form of cutaneous mastocytosis (MASTOCYTOSIS, CUTANEOUS) that occurs primarily in children. It is characterized by the multiple small reddish-brown pigmented pruritic macules and papules.
A family of neutral serine proteases with TRYPSIN-like activity. Tryptases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR.
A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of >20% MAST CELLS, multi-organ failure and a short survival.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Histamine substituted in any position with one or more methyl groups. Many of these are agonists for the H1, H2, or both histamine receptors.
A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation.
Removal of bone marrow and evaluation of its histologic picture.
A parasite of carnivorous mammals that causes TRICHINELLOSIS. It is especially common in rats and in swine fed uncooked garbage. Human infection is initiated by the consumption of raw or insufficiently cooked pork or other meat containing the encysted larvae.
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.
A solid tumor consisting of a dense infiltration of MAST CELLS. It is generally benign.
An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.
A multifunctional cytokine secreted by primarily by activated TH2 CELLS that may play a role as a regulator of allergic INFLAMMATION. It has been shown to enhance the growth and CELL DIFFERENTIATION of MAST CELLS, and can act on a variety of other immune cells.
Infections of the INTESTINES with PARASITES, commonly involving PARASITIC WORMS. Infections with roundworms (NEMATODE INFECTIONS) and tapeworms (CESTODE INFECTIONS) are also known as HELMINTHIASIS.
A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.
Physiologically active prostaglandins found in many tissues and organs. They show pressor activity, are mediators of inflammation, and have potential antithrombotic effects.
Infections caused by infestation with worms of the class Trematoda.
Class of parasitic flukes consisting of three subclasses, Monogenea, Aspidogastrea, and Digenea. The digenetic trematodes are the only ones found in man. They are endoparasites and require two hosts to complete their life cycle.
A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.
Abnormal increase of EOSINOPHILS in the blood, tissues or organs.
A low affinity interleukin-5 receptor subunit that combines with the CYTOKINE RECEPTOR COMMON BETA SUBUNIT to form a high affinity receptor for INTERLEUKIN-5. Several isoforms of the interleukin-5 receptor alpha subunit exist due to multiple ALTERNATIVE SPLICING.
Venoms from animals of the phylum Arthropoda. Those most investigated are from scorpions and spiders of the class Arachnidae and from ant, bee, and wasp families of the Insecta order Hymenoptera. The venoms contain protein toxins, enzymes, and other bioactive substances and may be lethal to man.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Pathological processes of the VULVA.

Cutaneous and systemic manifestations of mastocytosis. (1/170)

Mastocytosis is characterized by an excessive number of apparently normal mast cells in the skin and, occasionally, in other organs. Characteristic skin lesions, called urticaria pigmentosa, are present in most patients, but clinical presentation can vary from a pruritic rash to unexplained collapse and sudden death. These lesions are typically tan to red-brown macules that appear on the trunk and spread symmetrically. Patients with mastocytosis often have a long history of chronic and acute symptoms that were unrecognized as mastocytosis. Skin lesions may or may not accompany systemic mastocytosis. Systemic disease may involve the gastrointestinal tract, the bone marrow or other organs. Even when the disease is considered as a possibility by the physician, the diagnosis can be difficult because of special technical requirements necessary for biopsy and because of the problems with biochemical testing. Drug therapy is initiated to stabilize mast cell membranes, to reduce the severity of the attacks and to block the action of inflammatory mediators. The mainstay of therapy is histamine H1 and H2 blockers and the avoidance of triggering factors.  (+info)

Stem cell factor is localized in, released from, and cleaved by human mast cells. (2/170)

Stem cell factor (SCF) is the most important cytokine regulating human mast cell growth and functions. The immunogold technique showed SCF in the secretory granules of skin mast cells and in lung parenchymal mast cells (HLMC). Immunoreactive SCF (iSCF) was detected in cell lysates of HLMC, but not in basophils; iSCF and histamine were detected in supernatants of HLMC 3 min after challenge with anti-FcepsilonRI or anti-IgE, and iSCF in supernatants rapidly declined after 30 min, whereas histamine remained unchanged for 120 min. HPLC and electrospray mass spectrometry (ES/MS) analysis of recombinant human SCF1-166 (18,656. 9 +/- 0.9 Da) treated with chymase showed a polypeptide of 17,977.1 +/- 0.6 Da and a minor component of 697.4 +/- 0.1 Da generated by specific cleavage at Phe159. SCF1-166 and SCF1-159 similarly activated HLMC, potentiated anti-IgE-induced activation of these cells, and stimulated HLMC chemotaxis. SCF159-166 had no effect on mast cells. Western blot analysis of supernatants of anti-IgE-activated HLMC incubated with recombinant human SCF1-166 showed that SCF1-166 was rapidly cleaved to SCF1-159 and SCF1-144. Experiments with supernatants of anti-IgE-activated HLMC incubated with SCF1-166 yielded similar results. In conclusion, SCF is stored in mast cell secretory granules and is immunologically released by human mast cells. SCF1-166 is rapidly and specifically cleaved to SCF1-159 by chymase, which retains its biological effect on mast cells. SCF is also cleaved by other proteases to several SCF species whose possible biological activities remain to be established.  (+info)

An unusual presentation of systemic mastocytosis. (3/170)

A 47 year old man presented with mastocytosis, a disease process characterised by proliferation of mast cells. The clinical features and outcome are discussed.  (+info)

Cutaneous mucinosis and mastocytosis in a shar-pei. (4/170)

A 7-year-old shar-pei was presented because of a recurrent dermatologic condition. Skin biopsies revealed an idiopathic (primary) cutaneous mucinosis that initially responded to corticosteroids. The condition reappeared 2 years later and subsequent biopsies revealed a mast cell tumor in some of the skin sites previously diagnosed with mucinosis.  (+info)

c-Kit and c-kit mutations in mastocytosis and other hematological diseases. (5/170)

Mast cells (MC) are tissue elements derived from hematopoietic stem cells. Their differentiation and proliferation processes are under the influence of cytokines, including one of utmost importance known as stem cell factor (SCF). SCF receptor is encoded by the protooncogene c-kit, belongs to the type III receptor tyrosine kinase subfamily, and is also expressed on other hematopoietic or non-hematopoietic cells. Ligation of c-kit receptor by SCF induces its dimerization, followed by induction of multiple intracellular signaling pathways leading to cell proliferation and activation. Mastocytosis, a relatively rare group of diseases characterized by accumulation of MC in various tissues, are found isolated or sometimes associated with other hematological malignancies in humans. Although the initial events leading to mastocytosis are not yet unraveled, alterations of the c-kit gene have been described. Particularly interesting are acquired mutations resulting in a constitutively activated receptor, possibly involved in the increased numbers of MC in tissues. For this reason, future strategies might be envisaged to target specifically the mutated c-kit and/or its intracellular signaling.  (+info)

A role of mast cell glycosaminoglycans for the immunological expulsion of intestinal nematode, Strongyloides venezuelensis. (6/170)

We examined effects of mast cell glycosaminoglycans on the establishment of the intestinal nematode, Strongyloides venezuelensis, in the mouse small intestine. When intestinal mastocytosis occurred, surgically implanted adult worms could not invade and establish in the intestinal mucosa. In mast cell-deficient W/Wv mice, inhibition of adult worm invasion was not evident as compared with littermate +/+ control mice. Mucosal mastocytosis and inhibition of S. venezuelensis adult worm mucosal invasion was tightly correlated. To determine effector molecules for the invasion inhibition, adult worms were implanted with various sulfated carbohydrates including mast cell glycosaminoglycans. Among sulfated carbohydrates tested, chondroitin sulfate (ChS)-A, ChS-E, heparin, and dextran sulfate inhibited invasion of adult worms into intestinal mucosa in vivo. No significant inhibition was observed with ChS-C, desulfated chondroitin, and dextran. ChS-E, heparin, and dextran sulfate inhibited adhesion of S. venezuelensis adult worms to plastic surfaces in vitro. Furthermore, binding of intestinal epithelial cells to adhesion substances of S. venezuelensis, which have been implicated in mucosal invasion, was inhibited by ChS-E, heparin, and dextran sulfate. Because adult worms of S. venezuelensis were actively moving in the intestinal mucosa, probably exiting and reentering during infection, the possible expulsion mechanism for S. venezuelensis is inhibition by mast cell glycosaminoglycans of attachment and subsequent invasion of adult worms into intestinal epithelium.  (+info)

Nitric oxide mediates intestinal pathology but not immune expulsion during Trichinella spiralis infection in mice. (7/170)

The relationship between intestinal pathology and immune expulsion of gastrointestinal (GI) nematodes remains controversial. Although immune expulsion of GI helminth parasites is usually associated with Th2 responses, the effector mechanisms directly responsible for parasite loss have not been identified. We have previously shown that while the intestinal pathology accompanying the expulsion of the GI parasite Trichinella spiralis may be dependent on IL-4 and mediated by TNF, parasite loss is independent of TNF. In contrast, intestinal pathology in other disease models has been attributed to Th1 cytokines, although it closely resembles that seen in helminth infections. Whereas production of inducible NO synthase (iNOS) in the gut is important for both homeostasis of the epithelial layer and in protection against pathogenic microorganisms, overproduction of NO has been implicated in the pathogenesis of a number of inflammatory conditions. We therefore investigated the role of NO in T. spiralis infection using iNOS-deficient mice. iNOS-/- and iNOS-/+ mice were infected with T. spiralis, and parasite expulsion and intestinal pathology were followed. Parasite expulsion proceeded similarly in both groups of animals, but significant intestinal pathology was only observed in the heterozygous mice. Thus it appears that, although the protective effects of Th2 responses in GI helminth infection do not require NO, this mediator contributes substantially to the associated enteropathy. NO may therefore be an important mediator of enteropathy in both Th1- and Th2-inducing conditions.  (+info)

Pulmonary manifestation of systemic mast cell disease. (8/170)

Systemic mast cell disease is a rare disease of unknown aetiology. Systemic infiltration and proliferation of mast cells in skin, bone marrow, gastrointestinum and lymph nodes is the central pathological feature. This study reports a patient with mastocytosis of the skin (urticaria pigmentosa) for 10 yrs. The patient was referred to hospital for dyspnoea. Chest radiograph showed moderate reticular infiltration of both lungs, computerized tomography revealed multiple lymph nodes of the mediastinum and faint nodular lesions of middle and upper areas of lungs. Transbronchial biopsy demonstrated mast cell infiltration of the lung with formation of mast cell granuloma. According to the current literature, systemic mast cell disease with pulmonary involvement is a very rare entity. After a treatment with interferon alpha-2a over 6 months, the patient's condition and particularly dyspnoea showed improvement in parallel with an amelioration of the lesions as demonstrated by thorax computed tomography.  (+info)

Mastocytosis is a group of rare disorders caused by the accumulation of abnormal number of mast cells in various tissues of the body, particularly the skin and internal organs such as the bone marrow, liver, spleen, and gastrointestinal tract. Mast cells are types of white blood cells that play an important role in the immune system, releasing chemicals like histamine, heparin, and leukotrienes during allergic reactions or injury to help protect the body. However, excessive accumulation of mast cells can lead to chronic inflammation, tissue damage, and various symptoms.

There are two main types of mastocytosis: cutaneous mastocytosis (CM) and systemic mastocytosis (SM). CM primarily affects the skin, causing redness, itching, hives, and other skin abnormalities. SM, on the other hand, involves internal organs and can be more severe, with symptoms such as diarrhea, stomach pain, fatigue, bone pain, and anaphylaxis (a life-threatening allergic reaction).

Mastocytosis is typically caused by genetic mutations that lead to the overproduction of mast cells. The diagnosis of mastocytosis usually involves a combination of physical examination, medical history, blood tests, skin biopsy, and bone marrow aspiration. Treatment options depend on the type and severity of the disease and may include antihistamines, corticosteroids, chemotherapy, targeted therapy, and in severe cases, stem cell transplantation.

Systemic mastocytosis is a rare group of diseases characterized by the accumulation of abnormal number of mast cells in various organs and tissues of the body. Mast cells are a type of white blood cell that plays an important role in the immune system, particularly in allergic reactions and inflammation. In systemic mastocytosis, the excessive buildup of mast cells can cause a range of symptoms such as skin rashes, itching, gastrointestinal disturbances, bone pain, and in severe cases, organ damage or failure.

The diagnosis of systemic mastocytosis typically involves a combination of clinical evaluation, laboratory tests, imaging studies, and sometimes biopsies to confirm the presence of abnormal mast cells. Treatment for systemic mastocytosis depends on the severity and extent of the disease, but may include medications to manage symptoms, reduce mast cell activation and proliferation, and prevent complications. In some cases, cytoreductive therapies such as chemotherapy or stem cell transplantation may be recommended.

Cutaneous mastocytosis is a condition characterized by the abnormal accumulation of mast cells in the skin. Mast cells are a type of immune cell that releases chemicals such as histamine, heparin, and leukotrienes, which play a role in allergic reactions and inflammation. In cutaneous mastocytosis, the excessive buildup of mast cells can cause various skin symptoms, including redness, itching, swelling, and formation of lesions or tumors.

The condition is typically divided into several subtypes based on the age of onset and the clinical presentation. The most common form in children is called urticaria pigmentosa, which presents as small, reddish-brown spots or bumps that may become raised and itchy when scratched or rubbed (Darier's sign). In adults, a more severe form known as diffuse cutaneous mastocytosis can occur, where the entire skin becomes thickened, red, and swollen.

Cutaneous mastocytosis is usually diagnosed based on the patient's medical history, physical examination, and results from skin biopsies. Treatment typically focuses on relieving symptoms and preventing mast cell activation. Medications such as antihistamines, topical steroids, and mast cell stabilizers may be used to control itching, flushing, and other symptoms associated with the condition. In some cases, systemic therapies or phototherapy may also be recommended.

Urticaria pigmentosa is a rare mast cell disorder, characterized by the development of brownish-red, raised lesions (maculopapules) on the skin. These lesions are often found on the trunk and proximal extremities, but can occur anywhere on the body. They are typically asymptomatic, but may become itchy or even painful when subjected to friction, heat, or emotional stress. In some cases, these lesions may also release histamine, leading to symptoms such as flushing, headache, and hypotension. Urticaria pigmentosa is more common in children than adults, and typically resolves on its own over time. However, in some cases it can persist into adulthood or even progress to systemic mastocytosis, a more severe form of the disorder that can affect internal organs.

Tryptase is a type of enzyme that is found in the cells called mast cells, which are a part of the immune system. Specifically, tryptase is a serine protease, which means it helps to break down other proteins in the body. Tryptase is often released during an allergic reaction or as part of an inflammatory response. It can be measured in the blood and is sometimes used as a marker for mast cell activation or degranulation. High levels of tryptase may indicate the presence of certain medical conditions, such as systemic mastocytosis or anaphylaxis.

Proto-oncogene proteins c-kit, also known as CD117 or stem cell factor receptor, are transmembrane receptor tyrosine kinases that play crucial roles in various biological processes, including cell survival, proliferation, differentiation, and migration. They are encoded by the c-KIT gene located on human chromosome 4q12.

These proteins consist of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain. The binding of their ligand, stem cell factor (SCF), leads to receptor dimerization, autophosphorylation, and activation of several downstream signaling pathways such as PI3K/AKT, MAPK/ERK, and JAK/STAT.

Abnormal activation or mutation of c-kit proto-oncogene proteins has been implicated in the development and progression of various malignancies, including gastrointestinal stromal tumors (GISTs), acute myeloid leukemia (AML), mast cell diseases, and melanoma. Targeted therapies against c-kit, such as imatinib mesylate (Gleevec), have shown promising results in the treatment of these malignancies.

Mast cells are a type of white blood cell that are found in connective tissues throughout the body, including the skin, respiratory tract, and gastrointestinal tract. They play an important role in the immune system and help to defend the body against pathogens by releasing chemicals such as histamine, heparin, and leukotrienes, which help to attract other immune cells to the site of infection or injury. Mast cells also play a role in allergic reactions, as they release histamine and other chemicals in response to exposure to an allergen, leading to symptoms such as itching, swelling, and redness. They are derived from hematopoietic stem cells in the bone marrow and mature in the tissues where they reside.

Mast cell leukemia is a rare and aggressive type of leukemia, which is a cancer of the white blood cells. Specifically, mast cell leukemia affects a particular type of white blood cell called a mast cell. Mast cells are part of the immune system and play a role in allergic reactions and inflammation.

In mast cell leukemia, the bone marrow produces too many immature mast cells, which then enter the bloodstream. These abnormal mast cells can accumulate in various organs, such as the spleen, liver, and lymph nodes, causing damage and enlargement of these organs.

Symptoms of mast cell leukemia may include fatigue, weight loss, frequent infections, easy bruising or bleeding, bone pain, and enlarged lymph nodes. Diagnosis typically involves blood tests, bone marrow aspiration and biopsy, and imaging studies to assess the extent of organ involvement.

Mast cell leukemia is a very aggressive cancer with a poor prognosis, and treatment options are limited. Current treatments may include chemotherapy, stem cell transplantation, and targeted therapy with drugs that target specific molecular abnormalities in mast cells. However, the response to treatment is often not durable, and the disease can progress rapidly.

Bone marrow is the spongy tissue found inside certain bones in the body, such as the hips, thighs, and vertebrae. It is responsible for producing blood-forming cells, including red blood cells, white blood cells, and platelets. There are two types of bone marrow: red marrow, which is involved in blood cell production, and yellow marrow, which contains fatty tissue.

Red bone marrow contains hematopoietic stem cells, which can differentiate into various types of blood cells. These stem cells continuously divide and mature to produce new blood cells that are released into the circulation. Red blood cells carry oxygen throughout the body, white blood cells help fight infections, and platelets play a crucial role in blood clotting.

Bone marrow also serves as a site for immune cell development and maturation. It contains various types of immune cells, such as lymphocytes, macrophages, and dendritic cells, which help protect the body against infections and diseases.

Abnormalities in bone marrow function can lead to several medical conditions, including anemia, leukopenia, thrombocytopenia, and various types of cancer, such as leukemia and multiple myeloma. Bone marrow aspiration and biopsy are common diagnostic procedures used to evaluate bone marrow health and function.

Methylhistamines are not a recognized medical term or a specific medical condition. However, the term "methylhistamine" may refer to the metabolic breakdown product of the antihistamine drug, diphenhydramine, which is also known as N-methyldiphenhydramine or dimenhydrinate.

Diphenhydramine is a first-generation antihistamine that works by blocking the action of histamine, a chemical released during an allergic reaction. When diphenhydramine is metabolized in the body, it is converted into several breakdown products, including methylhistamines.

Methylhistamines are not known to have any specific pharmacological activity or clinical significance. However, they can be used as a marker for the presence of diphenhydramine or its metabolism in the body.

Chymases are a type of enzyme that belong to the family of serine proteases. They are found in various tissues and organs, including the heart, lungs, and immune cells called mast cells. Chymases play a role in several physiological and pathological processes, such as inflammation, tissue remodeling, and blood pressure regulation.

One of the most well-known chymases is found in the mast cells and is often referred to as "mast cell chymase." This enzyme can cleave and activate various proteins, including angiotensin I to angiotensin II, a potent vasoconstrictor that increases blood pressure. Chymases have also been implicated in the development of cardiovascular diseases, such as hypertension and heart failure, as well as respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD).

In summary, chymases are a group of serine protease enzymes that play important roles in various physiological and pathological processes, particularly in inflammation, tissue remodeling, and blood pressure regulation.

A bone marrow examination is a medical procedure in which a sample of bone marrow, the spongy tissue inside bones where blood cells are produced, is removed and examined. This test is used to diagnose or monitor various conditions affecting blood cell production, such as infections, leukemia, anemia, and other disorders of the bone marrow.

The sample is typically taken from the hipbone (iliac crest) or breastbone (sternum) using a special needle. The procedure may be done under local anesthesia or with sedation to minimize discomfort. Once the sample is obtained, it is examined under a microscope for the presence of abnormal cells, changes in cell size and shape, and other characteristics that can help diagnose specific conditions. Various stains, cultures, and other tests may also be performed on the sample to provide additional information.

Bone marrow examination is an important diagnostic tool in hematology and oncology, as it allows for a detailed assessment of blood cell production and can help guide treatment decisions for patients with various blood disorders.

"Trichinella spiralis" is a species of parasitic roundworm that causes the disease trichinosis in humans. The adult worms live in the intestine, where they produce larvae that migrate to striated muscle tissue, including the diaphragm, tongue, and skeletal muscles, where they encyst and form nurse cells. Infection typically occurs through the consumption of undercooked or raw meat, particularly pork, contaminated with the larvae. Symptoms can range from gastrointestinal disturbances to fever, muscle pain, and potentially life-threatening complications in severe cases. Prevention includes cooking meat thoroughly and freezing it at certain temperatures to kill the larvae.

Anaphylaxis is a severe, life-threatening systemic allergic reaction that occurs suddenly after exposure to an allergen (a substance that triggers an allergic reaction) to which the person has previously been sensitized. The symptoms of anaphylaxis include rapid onset of symptoms such as itching, hives, swelling of the throat and tongue, difficulty breathing, wheezing, cough, chest tightness, rapid heartbeat, hypotension (low blood pressure), shock, and in severe cases, loss of consciousness and death. Anaphylaxis is a medical emergency that requires immediate treatment with epinephrine (adrenaline) and other supportive measures to stabilize the patient's condition.

A mastocytoma is a type of tumor that develops from mast cells, which are a part of the immune system and play a role in allergic reactions and inflammation. Mastocytomas are most commonly found in the skin, but they can also occur in other organs such as the liver, spleen, and lymph nodes.

Mastocytomas are usually benign (non-cancerous), although malignant (cancerous) forms known as mast cell sarcomas can also occur. They typically appear as raised, red or brown lesions on the skin that may be itchy, painful, or bleed easily.

The diagnosis of a mastocytoma is usually made through a biopsy of the tumor, which involves removing a small sample of tissue for examination under a microscope. Treatment options for mastocytomas may include surgical removal, medication to manage symptoms such as itching or flushing, and in some cases, chemotherapy or radiation therapy.

Trichinellosis is a parasitic disease caused by the roundworm Trichinella spiralis. The infection typically occurs when contaminated raw or undercooked meat, often pork, is consumed. After ingestion, the larvae of the worm are released from the cysts in the meat and migrate to the small intestine, where they mature into adults.

The adult females then lay new larvae that penetrate the intestinal wall and travel through the bloodstream to striated muscle tissue (such as skeletal muscles), where they encapsulate and form new cysts. The symptoms of trichinellosis can vary widely, depending on the number of worms ingested and the intensity of infection. Early symptoms may include diarrhea, abdominal pain, nausea, vomiting, and fever. As the larvae migrate to muscle tissue, additional symptoms such as muscle pain, weakness, swelling of the face, eyelids, or tongue, and skin rashes can occur. Severe infections may lead to life-threatening complications, including heart and respiratory failure.

Prevention measures include cooking meat thoroughly (to an internal temperature of at least 160°F or 71°C), freezing meat properly (at -15°F or -26°C for several days) to kill the parasites, and avoiding consumption of raw or undercooked meat, especially from wild animals.

Interleukin-9 (IL-9) is a type of cytokine, which are small signaling proteins that mediate and regulate immunity, inflammation, and hematopoiesis. IL-9 is produced by several types of immune cells, including T cells (a type of white blood cell), mast cells, and eosinophils.

IL-9 plays a role in the development and function of various immune cells, and has been implicated in the pathogenesis of several inflammatory and allergic diseases, such as asthma, atopic dermatitis, and food allergy. It can promote the growth and survival of certain types of immune cells, including mast cells and B cells (another type of white blood cell), and can also enhance their activation and effector functions.

In addition to its role in immunity and inflammation, IL-9 has been shown to play a role in the development and progression of some types of cancer, such as lung cancer and leukemia. However, more research is needed to fully understand the complex functions of this cytokine and its potential as a therapeutic target.

Parasitic intestinal diseases are disorders caused by microscopic parasites that invade the gastrointestinal tract, specifically the small intestine. These parasites include protozoa (single-celled organisms) and helminths (parasitic worms). The most common protozoan parasites that cause intestinal disease are Giardia lamblia, Cryptosporidium parvum, and Entamoeba histolytica. Common helminthic parasites include roundworms (Ascaris lumbricoides), tapeworms (Taenia saginata and Taenia solium), hookworms (Ancylostoma duodenale and Necator americanus), and pinworms (Enterobius vermicularis).

Parasitic intestinal diseases can cause a variety of symptoms, including diarrhea, abdominal pain, bloating, nausea, vomiting, fatigue, and weight loss. The severity and duration of the symptoms depend on the type of parasite, the number of organisms present, and the immune status of the host.

Transmission of these parasites can occur through various routes, including contaminated food and water, person-to-person contact, and contact with contaminated soil or feces. Preventive measures include practicing good hygiene, washing hands thoroughly after using the toilet and before handling food, cooking food thoroughly, and avoiding consumption of raw or undercooked meat, poultry, or seafood.

Treatment of parasitic intestinal diseases typically involves the use of antiparasitic medications that target the specific parasite causing the infection. In some cases, supportive care such as fluid replacement and symptom management may also be necessary.

Hydroxyzine is an antihistamine medication that is primarily used to treat symptoms of allergies such as itching, hives, and swelling. It works by blocking the effects of histamine, a substance in the body that causes allergic reactions. In addition to its antihistaminic properties, hydroxyzine also has sedative and anxiety-reducing effects, which make it useful in treating anxiety disorders, symptoms of alcohol withdrawal, and as a sleep aid. It is available in both oral and injectable forms and is usually taken orally in the form of tablets, capsules, or syrup. As with any medication, hydroxyzine should be used under the supervision of a healthcare provider, and its use may be subject to certain precautions and contraindications depending on the individual's medical history and current health status.

I'm sorry for any confusion, but "Prostaglandins D" is not a recognized or established term in the field of medicine or physiology. Prostaglandins are a group of lipid compounds that are synthesized in the body from fatty acids and have diverse hormone-like effects in the body. They are classified into several types based on their chemical structure and biological activity, including Prostaglandin D (PGD), but referring to "Prostaglandins D" as a single entity is not standard.

Prostaglandin D (PGD) itself is a type of prostaglandin that is rapidly converted to other compounds in the body and has been studied for its potential role in various physiological processes, such as inflammation, fever, and blood flow regulation. However, it's important to note that specific medical definitions or clinical uses related to "Prostaglandins D" are not well-established.

If you have any further questions or need more information about a specific aspect of prostaglandins or their role in the body, I would be happy to help!

Trematode infections, also known as trematodiasis or fluke infections, are parasitic diseases caused by various species of flatworms called trematodes. These parasites have an indirect life cycle involving one or two intermediate hosts (such as snails or fish) and a definitive host (usually a mammal or bird).

Humans can become accidentally infected when they consume raw or undercooked aquatic plants, animals, or contaminated water that contains the larval stages of these parasites. The most common trematode infections affecting humans include:

1. Schistosomiasis (also known as bilharzia): Caused by several species of blood flukes (Schistosoma spp.). Adult worms live in the blood vessels, and their eggs can cause inflammation and damage to various organs, such as the liver, intestines, bladder, or lungs.
2. Liver flukes: Fasciola hepatica and Fasciola gigantica are common liver fluke species that infect humans through contaminated watercress or other aquatic plants. These parasites can cause liver damage, abdominal pain, diarrhea, and eosinophilia (elevated eosinophil count in the blood).
3. Lung flukes: Paragonimus spp. are lung fluke species that infect humans through consumption of raw or undercooked crustaceans. These parasites can cause coughing, chest pain, and bloody sputum.
4. Intestinal flukes: Various species of intestinal flukes (e.g., Haplorchis spp., Metagonimus yokogawai) infect humans through consumption of raw or undercooked fish. These parasites can cause abdominal pain, diarrhea, and eosinophilia.
5. Eye fluke: The oriental eye fluke (Drepanotrema spp.) can infect the human eye through contaminated water. It can cause eye inflammation, corneal ulcers, and vision loss.

Prevention measures include avoiding consumption of raw or undercooked aquatic plants, animals, and their products; practicing good hygiene; and treating drinking water to kill parasites. Treatment typically involves administering anthelmintic drugs such as praziquantel, albendazole, or mebendazole, depending on the specific fluke species involved.

Trematoda is a class of parasitic flatworms, also known as flukes. They have a complex life cycle involving one or more intermediate hosts and a definitive host. Adult trematodes are typically leaf-shaped and range in size from a few millimeters to several centimeters.

They have a characteristic oral sucker surrounding the mouth and a ventral sucker, which they use for locomotion and attachment to their host's tissues. Trematodes infect various organs of their hosts, including the liver, lungs, blood vessels, and intestines, causing a range of diseases in humans and animals.

Examples of human-infecting trematodes include Schistosoma spp., which cause schistosomiasis (also known as bilharzia), and Fasciola hepatica, which causes fascioliasis (liver fluke disease). Trematode infections are typically treated with antiparasitic drugs.

Stem Cell Factor (SCF), also known as Kit Ligand or Steel Factor, is a growth factor that plays a crucial role in the regulation of hematopoiesis, which is the process of producing various blood cells. It is a glycoprotein that binds to the c-Kit receptor found on hematopoietic stem cells and progenitor cells, promoting their survival, proliferation, and differentiation into mature blood cells.

SCF is involved in the development and function of several types of blood cells, including red blood cells, white blood cells, and platelets. It also plays a role in the maintenance and self-renewal of hematopoietic stem cells, which are essential for the continuous production of new blood cells throughout an individual's lifetime.

In addition to its role in hematopoiesis, SCF has been implicated in various other biological processes, such as melanogenesis, gametogenesis, and tissue repair and regeneration. Dysregulation of SCF signaling has been associated with several diseases, including certain types of cancer, bone marrow failure disorders, and autoimmune diseases.

Eosinophilia is a medical condition characterized by an abnormally high concentration of eosinophils in the circulating blood. Eosinophils are a type of white blood cell that play an important role in the immune system, particularly in fighting off parasitic infections and regulating allergic reactions. However, when their numbers become excessively high, they can contribute to tissue damage and inflammation.

Eosinophilia is typically defined as a count of more than 500 eosinophils per microliter of blood. Mild eosinophilia (up to 1,500 cells/μL) may not cause any symptoms and may be discovered during routine blood tests. However, higher levels of eosinophilia can lead to various symptoms such as coughing, wheezing, skin rashes, and organ damage, depending on the underlying cause.

The causes of eosinophilia are varied and can include allergic reactions, parasitic infections, autoimmune disorders, certain medications, and some types of cancer. Accurate diagnosis and treatment of eosinophilia require identification and management of the underlying cause.

The Interleukin-5 Receptor alpha Subunit (IL-5Rα) is a protein that forms part of the Type I cytokine receptor, specifically for the interleukin-5 (IL-5) cytokine. This receptor is found on the surface of hematopoietic cells, such as eosinophils and basophils. The binding of IL-5 to the IL-5Rα subunit initiates intracellular signaling cascades that regulate the growth, activation, differentiation, and survival of eosinophils and basophils, which are crucial in the immune response against parasitic infections and allergic reactions. Mutations in the gene encoding IL-5Rα can lead to altered immune responses and diseases such as hypereosinophilic syndromes.

Arthropod venoms are toxic secretions produced by the venom glands of various arthropods, such as spiders, scorpions, insects, and marine invertebrates. These venoms typically contain a complex mixture of bioactive molecules, including peptides, proteins, enzymes, and small molecules, which can cause a range of symptoms and effects in humans and other animals.

The specific composition of arthropod venoms varies widely depending on the species and can be tailored to serve various functions, such as prey immobilization, defense, or predation. Some arthropod venoms contain neurotoxins that can disrupt nerve function and cause paralysis, while others may contain cytotoxins that damage tissues or hemotoxins that affect the blood and cardiovascular system.

Arthropod venoms have been studied for their potential therapeutic applications, as some of their bioactive components have shown promise in treating various medical conditions, including pain, inflammation, and neurological disorders. However, it is important to note that arthropod venoms can also cause severe allergic reactions and other adverse effects in susceptible individuals, making it essential to exercise caution when handling or coming into contact with venomous arthropods.

A biopsy is a medical procedure in which a small sample of tissue is taken from the body to be examined under a microscope for the presence of disease. This can help doctors diagnose and monitor various medical conditions, such as cancer, infections, or autoimmune disorders. The type of biopsy performed will depend on the location and nature of the suspected condition. Some common types of biopsies include:

1. Incisional biopsy: In this procedure, a surgeon removes a piece of tissue from an abnormal area using a scalpel or other surgical instrument. This type of biopsy is often used when the lesion is too large to be removed entirely during the initial biopsy.

2. Excisional biopsy: An excisional biopsy involves removing the entire abnormal area, along with a margin of healthy tissue surrounding it. This technique is typically employed for smaller lesions or when cancer is suspected.

3. Needle biopsy: A needle biopsy uses a thin, hollow needle to extract cells or fluid from the body. There are two main types of needle biopsies: fine-needle aspiration (FNA) and core needle biopsy. FNA extracts loose cells, while a core needle biopsy removes a small piece of tissue.

4. Punch biopsy: In a punch biopsy, a round, sharp tool is used to remove a small cylindrical sample of skin tissue. This type of biopsy is often used for evaluating rashes or other skin abnormalities.

5. Shave biopsy: During a shave biopsy, a thin slice of tissue is removed from the surface of the skin using a sharp razor-like instrument. This technique is typically used for superficial lesions or growths on the skin.

After the biopsy sample has been collected, it is sent to a laboratory where a pathologist will examine the tissue under a microscope and provide a diagnosis based on their findings. The results of the biopsy can help guide further treatment decisions and determine the best course of action for managing the patient's condition.

Vulvar diseases refer to a range of medical conditions that affect the vulva, which is the external female genital area including the mons pubis, labia majora and minora, clitoris, and the vaginal opening. These conditions can cause various symptoms such as itching, burning, pain, soreness, irritation, or abnormal growths or lesions. Some common vulvar diseases include:

1. Vulvitis: inflammation of the vulva that can be caused by infection, allergies, or irritants.
2. Lichen sclerosus: a chronic skin condition that causes thin, white patches on the vulva.
3. Lichen planus: an inflammatory condition that affects the skin and mucous membranes, including the vulva.
4. Vulvar cancer: a rare type of cancer that develops in the tissues of the vulva.
5. Genital warts: caused by human papillomavirus (HPV) infection, these are small growths or bumps on the vulva.
6. Pudendal neuralgia: a nerve condition that causes pain in the vulvar area.
7. Vestibulodynia: pain or discomfort in the vestibule, the area surrounding the vaginal opening.

It is important to consult a healthcare professional if experiencing any symptoms related to vulvar diseases for proper diagnosis and treatment.

... can occur in a variety of forms: The most common cutaneous mastocytosis is maculopapular cutaneous mastocytosis, ... Indolent systemic mastocytosis (ISM). The most common SM (>90%) Smouldering systemic mastocytosis (SSM) Systemic mastocytosis ... "Mastocytosis & mast cell disorders". Mastocytosis Society Canada. Archived from the original on 2013-12-28. Retrieved 2017-11- ... The true incidence and prevalence of mastocytosis is unknown, but mastocytosis generally has been considered to be an "orphan ...
Mastocytosis. 38 (3): 497-504. doi:10.1016/j.iac.2018.04.004. PMID 30007466. S2CID 51628256. Cheung I, Vadas P (2015). "A New ...
Most treatments for mastocytosis can be used to treat urticaria pigmentosa. Many common anti-allergy medications are useful ... "Urticaria pigmentosa (mastocytosis). DermNet NZ". dermnetnz.org. Archived from the original on 2004-06-04. Fairley JA, Pentland ... Yanagihori H, Oyama N, Nakamura K, Kaneko F (2005). "c-kit Mutations in Patients with Childhood-Onset Mastocytosis and Genotype ... Urticaria pigmentosa (also known as generalized eruption of cutaneous mastocytosis (childhood type): 616 ) is the most common ...
Castells is a leader in the mastocytosis treatment and research field, and directs both the Mastocytosis Center of Excellence ... Mastocytosis is a rare disease with limited treatment options. Castells works at Brigham and Women's Hospital in Massachusetts ... She is also part of the medical advisory board for The Mastocytosis Society. Castells leads clinical trials related to both ... "Mastocytosis (cutaneous and systemic): Evaluation and diagnosis in adults". UpToDate. Retrieved 2020-01-16. "Bad Allergies, Yes ...
"Bone Disease in Mastocytosis". Immunology and Allergy Clinics of North America. 38 (3): 443-454. doi:10.1016/j.iac.2018.04.013 ... Osteosclerosing types of chronic osteomyelitis Hypervitaminosis D hyperparathyroidism Schnitzler syndrome Mastocytosis Skeletal ...
Mastocytosis is a rare clonal mast cell disorder involving the presence of too many mast cells (mastocytes) and CD34+ mast cell ... Mutations in c-Kit are associated with mastocytosis. Mastocytomas, or mast cell tumors, can secrete excessive quantities of ... Horny HP, Sotlar K, Valent P (2007). "Mastocytosis: state of the art". Pathobiology. 74 (2): 121-32. doi:10.1159/000101711. ... considers mastocytosis and carcinoid syndrome, and is treated with H1 and H2 antihistamines, epinephrine, and steroids [21, 22 ...
617 Mastocytosis Skin lesion James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical ...
615 Mastocytosis Skin lesion James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical ...
It may also be used as an adjunct therapy in symptomatic treatment of mastocytosis. It is taken by mouth, as a tablet, chewable ... Cardet JC, Akin C, Lee MJ (October 2013). "Mastocytosis: update on pharmacotherapy and future directions". Expert Opinion on ...
... is also indicated for the treatment of adults with advanced systemic mastocytosis, aggressive systemic mastocytosis ... Ayvakit was granted approval for advanced systemic mastocytosis by the FDA on June 16, 2021. "Ayvakit- avapritinib tablet, film ... "FDA approves avapritinib for advanced systemic mastocytosis". U.S. Food and Drug Administration (FDA). 16 June 2021. Retrieved ... Research, Center for Drug Evaluation and (16 June 2021). "FDA approves avapritinib for advanced systemic mastocytosis". FDA. Wu ...
In 2001, 2008 and 2016 he drew book chapters on mastocytosis as the author of the WHO. Peter Valent is one of the most ... From 2002 he coordinates the European Competence Network on Mastocytosis and since 2008 he is Scientific Director of the Ludwig ... In the forthcoming years, the diagnostic WHO criteria of mastocytosis were validated, adjusted and extended. To discuss these ... Valent, Peter (1 June 2010). "Classification and response criteria in mastocytosis: is there a need to revise?". Expert Review ...
Patnaik MM, Tefferi A, Pardanani A (August 2007). "Kit: molecule of interest for the diagnosis and treatment of mastocytosis ... Gupta R, Bain BJ, Knight CL (2002). "Cytogenetic and molecular genetic abnormalities in systemic mastocytosis". Acta ...
Horan RF, Sheffer AL, Austen KF (May 1990). "Cromolyn sodium in the management of systemic mastocytosis". The Journal of ... to treat mastocytosis, mast cell activation syndrome, dermatographic urticaria and ulcerative colitis. Another oral product, ...
Over 95% of patients with adult onset systemic mastocytosis and approximately 40% of children with cutaneous mastocytosis are ... In an open-label study of patients with mastocytosis-related organ damage (89 eligible patients meeting inclusion for the ... Midostaurin is an investigational treatment in patients with advanced forms of systemic mastocytosis and D816V c-Kit mutation ... June 2016). "Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis". The New England Journal of Medicine. 374 ( ...
Mastocytosis is a rare disease in which there is a proliferation of mast cells that produce excess histamine. Some people may ... July 2001). "Diagnostic criteria and classification of mastocytosis: a consensus proposal". Leukemia Research. 25 (7): 603-25. ...
In a small proportion of cases, acute mast cell leukemia may evolve from a more progressive form of systemic mastocytosis. The ... June 2002). "Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for ... November 2004), "Histidine carboxylase (HDC) as novel marker of immature neoplastic mast cells in systemic mastocytosis", Blood ... July 2001). "Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis". Leuk. Res. 25 (7): 595- ...
616 Mastocytosis Skin lesion List of cutaneous conditions James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' ...
Previously, they were known as myeloproliferative diseases (MPD). In 2016, Mastocytosis was no longer classified as an MPN. " ...
"Mixed organic brain syndrome as a manifestation of systemic mastocytosis". Psychosomatic Medicine. 48 (6): 437-47. doi:10.1097/ ... alcohol use disorder Non-medical use of sedative hypnotics Intracranial hemorrhage/trauma Korsakoff syndrome Mastocytosis ...
Also referred to as SM-eo (systemic mastocytosis with eosinophilia) or SM-SEL (systemic mastocytosis with chronic eosinophilic ... For example, eosinophilia occurs in 20% to 30% of patients with systemic mastocytosis. ... systemic mastocytosis, etc.) (see causes of eosinophilia). Absent these causes, patients were diagnosed in the World Health ... "Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis". Current ...
Dermatographism may occur in mastocytosis (systemic mast cell proliferation). This condition is diagnosed by a health care ...
He died in Vienna of mastocytosis at the age of 50. Czernin was portrayed by actor Daniel Brühl in the 2015 film Woman in Gold ... Deaths from mastocytosis, 1956 births, 2006 deaths, 21st-century Austrian journalists). ...
May 2009). "Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates". Leukemia. 23 (5 ...
One study demonstrated that imatinib mesylate was effective in patients with systemic mastocytosis, including those who had the ... and aggressive systemic mastocytosis (ASM). Imatinib is considered to be a very effective treatment for CML, and has been shown ... of cases of mastocytosis. Imatinib was initially thought to have a potential role in the treatment of pulmonary hypertension. ... aggressive systemic mastocytosis without or an unknown D816V c-KIT mutation, hypereosinophilic syndrome and/or chronic ...
Theodore Maiman, 79, American physicist who built the first laser, systemic mastocytosis. Edwin H. Simmons, 85, American Marine ...
This systemic mastocytosis is observed mainly in animals in which a mastocytoma has previously been removed. It is accompanied ... In systemic mastocytosis, a decrease in white blood cells (leukopenia) often occurs. Circulating mast cells in the blood are ... The D816V mutation is the most common of these c-KIT mutations and occurs in 80% of patients with mastocytosis. However, there ... In total, there are over 20 known chromosomal alterations in humans that can lead to mastocytosis, with chromosomes 2, 7, 12, ...
"Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis". Current ...
"Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis". Current ...
Those with mastocytosis or of a higher socioeconomic status are at increased risk. Anaphylaxis is a severe allergic reaction of ...
... in Cutaneous Mastocytosis". New England Journal of Medicine. 328 (18): 1302-1307. doi:10.1056/NEJM199305063281803. PMID 7682288 ...
Mastocytosis can occur in a variety of forms: The most common cutaneous mastocytosis is maculopapular cutaneous mastocytosis, ... Indolent systemic mastocytosis (ISM). The most common SM (>90%) Smouldering systemic mastocytosis (SSM) Systemic mastocytosis ... "Mastocytosis & mast cell disorders". Mastocytosis Society Canada. Archived from the original on 2013-12-28. Retrieved 2017-11- ... The true incidence and prevalence of mastocytosis is unknown, but mastocytosis generally has been considered to be an "orphan ...
Cutaneous mastocytosis Urticaria pigmentosa Maculopapular cutaneous mastocytosis Diffuse cutaneous mastocytosis Mas... ... The World Health Organization (WHO) classification of mastocytosis includes the following: ... Mastocytosis is a disorder characterized by mast cell proliferation and accumulation within various organs, most commonly the ... Types of cutaneous mastocytosis include solitary mastocytoma, diffuse erythrodermic mastocytosis, paucicellular mastocytosis ( ...
Although systemic mastocytosis triggers vary from person to person, these healthy habits may help. ... Advanced Systemic Mastocytosis: Your FAQs. There is no cure for advanced systemic mastocytosis, but many of the symptoms can be ... Systemic Mastocytosis: What to Know. The accumulation of mast cells in various organs that occurs with systemic mastocytosis ... Systemic mastocytosis is rare, so you may not find a dedicated support group in your area. But you can seek support and ...
Mastocytosis is variable in respect to the organ syste … ... Mastocytosis is a disease characterized by an abnormal increase ... Mastocytosis is a disease characterized by an abnormal increase in mast cells. Manifestations of the disease are provoked in ... Classification and diagnosis of mastocytosis: current status J Invest Dermatol. 1991 Mar;96(3):2S-4S. ... Mastocytosis is variable in respect to the organ systems involved, clinical manifestations, and association with hematologic ...
Raise free funds for The UK Mastocytosis Support Group today by shopping online via Easyfundraising. Click now to shop at no ... About The UK Mastocytosis Support Group. The UK Mastocytosis Support Group provides support to people with mastocytosis and ... Youll be able to see how much youve raised in your account and well send updates on when The UK Mastocytosis Support Group ...
The following factors may raise a persons risk of developing mastocytosis:. * Age. Most often, cutaneous mastocytosis begins ... Changed or mutated forms of the c-kit gene may cause some types of mastocytosis, including systemic mastocytosis. ... Mastocytosis: Risk Factors. Approved by the Cancer.Net Editorial Board, 06/2017 ... Some people with several risk factors never develop mastocytosis, while others with no known risk factors do. Knowing your risk ...
... whether classical urticaria pigmentosa in children or adult mastocytosis - I usually ask a directed review of systems, focusing ... What about children with mastocytosis? In a pilot study that surveyed the parents of 17 children with mastocytosis, including ... When following patients with mastocytosis - whether classical urticaria pigmentosa in children or adult mastocytosis - I ... "Brain fog" and mastocytosis: In patients and me. By Warren R. Heymann, MD. Dec. 4, 2016. ...
... High Quality Pathology Images of Hematopathology: Myeloid, Histiocytic & Dendritic Cell Neoplasms of Mastocytosis ... Mastocytosis. Reviewer(s): Jayalakshmi Venkateswaran, MD; Dharam M. Ramnani, MD Home "> Hematopathology "> Myeloid, Histiocytic ... Focused Mastocytosis with stained slides of pathology. ... Systemic Mastocytosis : GI Tract. Systemic Mastocytosis : GI ...
Mastocytosis is a diverse group of disorders characterised by the expansion and accumulation of mast cells in one or more organ ... Cutaneous mastocytosis. There are three main forms of cutaneous mastocytosis:. *Maculopapular cutaneous mastocytosis (urticaria ... There is no known way to prevent mastocytosis. What is the outcome for mastocytosis?. Cutaneous mastocytosis is usually self- ... See more images of cutaneous mastocytosis. Who gets mastocytosis?. Mastocytosis can occur at any age, although some types are ...
Gene context of Mastocytosis, Systemic. *CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis ... Chemical compound and disease context of Mastocytosis, Systemic. *Treatment of adult systemic mastocytosis with a PAF-acether ... Biological context of Mastocytosis, Systemic. *We report on a patient with systemic mastocytosis with an activating point ... Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis ...
What workup is needed for a patient with mastocytosis diagnosed through biopsy? ... Cutaneous mastocytosis has skin lesions with typical clinical signs (i.e., urticaria pigmentosa, diffuse cutaneous mastocytosis ... or diffuse mastocytosis infiltrates (,20 cells per high-power field) or (2) c-KIT D816V mutation. Systemic mastocytosis ... What workup is needed for a patient with mastocytosis diagnosed through biopsy? The rash, which covers his arms and trunk and ...
Mastocytosis is a heterogeneous group of diseases defined by an increased number and accumulation of mast cells, and often also ... Mastocytosis affects people of all ages and has been considered rare; however, it is probably underdiagnosed with potential ... Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. Publikation: Bidrag til tidsskrift › ... consensus recommendations from a Nordic expert group for the diagnosis and general management of patients with mastocytosis. ...
WHO classified four major subtypes of extracutaneous systemic mastocytosis: (1) indolent systemic mastocytosis, (2) systemic ... Mastocytosis in adults Print Images (29) Contributors: Vanessa Holland MD, Jeffrey D. Bernhard MD, Belinda Tan MD, PhD, Noah ... aggressive systemic mastocytosis, and (4) mast cell leukemia. *Indolent systemic mastocytosis is most frequently seen. Mast ... Aggressive systemic mastocytosis, in which there is organ destruction from a mast cell infiltrate, is rare and should promote ...
Allergy School on Insect Venom Allergy and Mastocytosis - Scientific Programme ...
16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neoplasm, and 16 had mast- ... Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N. Engl. J. Med., 374 (26). S. 2530 - 2542. WALTHAM: ... BACKGROUND Advanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor prognosis and ... Response rates were similar regardless of the subtype of advanced systemic mastocytosis, KIT mutation status, or exposure to ...
... slide set presents an expert discussion detailing the limitations of conventional treatments for indolent systemic mastocytosis ... Director, Mastocytosis Center. Brigham and Womens Hospital. Professor of Medicine. Harvard Medical School. Boston, ... slide set presents an expert discussion detailing the limitations of conventional treatments for indolent systemic mastocytosis ...
Mastocytosis is a disease characterized by the presence of purple-brown spots on the skin and the plane of internal organs as a ... Mastocytosis. Leave a Comment / By admin / October 6, 2022 Mastocytosis. Mastocytosis is a disease characterized by the ... Systemic mastocytosis - mast cells infiltrate the bone marrow, liver, spleen, lymph nodes, gastrointestinal tract, skin and ... Cutaneous mastocytosis and urticaria pigmentosa do not often require treatment. Possible surgical treatment for cosmetic ...
Mastocytosis is caused by build-up of mast cells in the tissues (Table I). It is a rare but not exceptional disorder which can ...
SM, systemic mastocytosis. Mastocytosis (mast cell disease) is a relatively uncommon haematological tumour of bone marrow ... A diagnosis of mastocytosis should not be made on the basis of such findings alone; Giemsa stain. (C) Immunostaining with an ... Horny H-P, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol1985;16:808-14. ... It was also shown that the diagnostic criteria included in the new system of classification of mastocytosis need to be strictly ...
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison ... Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison ... Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison ...
Systemic mastocytosis is a life-threatening disease in which mast cell mediator release can lead to general symptoms. The most ... Systemic mastocytosis is a life-threatening disease in which mast cell mediator release can lead to general symptoms. The most ... Management of labor and delivery by spinal and epidural analgesia in a woman with systemic mastocytosis: a case report ... We report the management of labor and delivery in a case with severe systemic mastocytosis by epidural analgesia. ...
... cutaneous mastocytosis. The consultant told me I had 1 in 10 chance of it turning systemic and 1 in 100 chance of bone marrow ...
Mastocytosis Mastocytosis is the abnormal growth of cells from the immune system in your body. It can occur in people of… ...
Round table discussion: Midostaurin as an emerging therapy in FLT3+ AML in advanced systemic mastocytosis. *Van der Straeten, J ...
Mastocytosis is the abundance of mast cells. It can be due to a number of causes. ... 2011). "Systemic mastocytosis (SM) and associated malignant bone marrow histiocytosis - a hitherto undescribed form of SM-AHNMD ... Arock, M.; Valent, P. (Aug 2010). "Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and ... Retrieved from "https://librepathology.org/w/index.php?title=Mastocytosis&oldid=48813" ...
Cutaneous mastocytosis (urticaria pigmentosa and diffuse cutaneous mastocytosis) shows a disseminated appearance on the entire ... The 2016 updated current WHO classification of mastocytosis identifies 3 forms of cutaneous mastocytosis: urticaria pigmentosa ... Localized mastocytosis (mastocytoma) is a single lesion (or sometimes 1-3 lesions), most often found in children. Mastocytosis ... A. Abid, M.A. Malone, K. Curci: Mastocytosis (2016) * K. Hartmann, L. Escribano, C. Grattan, et al.: Cutaneous manifestations ...
"Mastocytosis" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Mastocytosis" by people in this website by year, and whether " ... A heterogenous group of disorders characterized by the abnormal increase of MAST CELLS in only the skin (MASTOCYTOSIS, ... Below are the most recent publications written about "Mastocytosis" by people in Profiles. ...
2. Classification of mastocytosis. Mastocytosis can be divided in WHO classification into 7 variants: cutaneous mastocytosis ( ... In general mastocytosis is not a genetic disease, a germline mutations of KIT gene in children with mastocytosis were rare, ... Indolent systemic mastocytosis is the most common and least serious presentation of systemic mastocytosis in adults - it is ... Cutaneous mastocytosis. Cutaneous mastocytosis (CM) is usually diagnosed by its clinical appearance and positive Darier sign. ...
Systemic mastocytosis. MedlinePlus Genetics provides information about Systemic mastocytosis. More About This Health Condition ...
  • Diagnosis of urticaria pigmentosa (cutaneous mastocytosis, see above) can often be done by seeing the characteristic lesions that are dark brown and fixed. (wikipedia.org)
  • Mastocytosis can occur in a variety of forms: The most common cutaneous mastocytosis is maculopapular cutaneous mastocytosis, previously named papular urticaria pigmentosa (UP), more common in children, although also seen in adults. (wikipedia.org)
  • Telangiectasia macularis eruptiva perstans (TMEP) is a much rarer form of cutaneous mastocytosis that affects adults. (wikipedia.org)
  • This article focuses on cutaneous mastocytosis (CM). The single World Health Organization (WHO) major criterion is multifocal dense infiltrates of mast cells in bone marrow and/or other extracutaneous organs. (medscape.com)
  • Types of cutaneous mastocytosis include solitary mastocytoma, diffuse erythrodermic mastocytosis, paucicellular mastocytosis (also termed telangiectasia macularis eruptiva perstans [TMEP]), and urticaria pigmentosa (UP). (medscape.com)
  • [ 11 ] Increased local concentrations of soluble mast cell growth factor in lesions of cutaneous mastocytosis are believed to stimulate mast cell proliferation, melanocyte proliferation, and melanin pigment production. (medscape.com)
  • Most often, cutaneous mastocytosis begins during infancy and early childhood. (cancer.net)
  • Cutaneous mastocytosis is most commonly diagnosed in childhood. (dermnetnz.org)
  • Rare and severe form of cutaneous mastocytosis. (dermnetnz.org)
  • Mastocytosis most commonly manifests as cutaneous disease ( urticaria pigmentosa , mastocytoma ), seen more often in children with involvement typically limited to the skin. (logicalimages.com)
  • Cutaneous mastocytosis and urticaria pigmentosa do not often require treatment. (medprep.info)
  • With the exception of pure cutaneous mastocytosis (usually urticaria pigmentosa), indolent SM affecting bone marrow and skin is the most common subvariant of mastocytosis. (bmj.com)
  • He referred me to the hospital - they did a biopsy and confirmed urticaria pigmentosa, cutaneous mastocytosis. (ukmasto.org)
  • Diffuse cutaneous mastocytosis: diffuse erythema, skin infiltration, blistering (rare, in the first month of life). (cyberderm.net)
  • Cutaneous mastocytosis (urticaria pigmentosa and diffuse cutaneous mastocytosis) shows a disseminated appearance on the entire body. (cyberderm.net)
  • The 2016 updated current WHO classification of mastocytosis identifies 3 forms of cutaneous mastocytosis: urticaria pigmentosa, diffuse cutaneous mastocytosis, and mastocytoma. (cyberderm.net)
  • A heterogenous group of disorders characterized by the abnormal increase of MAST CELLS in only the skin (MASTOCYTOSIS, CUTANEOUS), in extracutaneous tissues involving multiple organs (MASTOCYTOSIS, SYSTEMIC), or in solid tumors (MASTOCYTOMA). (sdsu.edu)
  • There are three main types: cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma. (qxmd.com)
  • Mastocytosis can be categorized into cutaneous mastocytosis and systemic mastocytosis. (ab-science.com)
  • In cutaneous mastocytosis , the mast cells accumulate only in the skin. (osmosis.org)
  • For example, in the most common form of cutaneous mastocytosis , lesions appear on the skin's surface as brownish, flat or elevated spots. (osmosis.org)
  • cutaneous mastocytosis, which only affects the skin, and systemic mastocytosis, which involves multiple organs. (osmosis.org)
  • Cutaneous mastocytosis usually occurs in children. (msdmanuals.com)
  • Mastocytosis incorporates a heterogeneous gathering of clonal sicknesses, including cutaneous mastocytosis (CM), foundational mastocytosis (SM), and pole cell sarcoma (MCS). (md-fm.com)
  • Cutaneous mastocytosis is the most successive type of pole cell infection, representing 90% of cases. (md-fm.com)
  • In cutaneous mastocytosis, the accelerated numbers of mast cells are located only inside the pores and skin. (usa-good.com)
  • Mastocytosis can occur in each youngsters and adults, with a predominance for cutaneous mastocytosis in youngsters and systemic mastocytosis in adults. (usa-good.com)
  • Patients with cutaneous mastocytosis experienced more mast cell-mediated symptoms than did those with indolent mastocytosis. (medscape.com)
  • When following patients with mastocytosis - whether classical urticaria pigmentosa in children or adult mastocytosis - I usually ask a directed review of systems, focusing on flushing, palpitations, and gastrointestinal symptoms. (aad.org)
  • Urticaria pigmentosa is found in most patients with mastocytosis. (clinicaladvisor.com)
  • Urticaria pigmentosa (maculopapular mastocytosis): many red-brown, maculopapular lesions, with variable flushes and pruritus (most common form). (cyberderm.net)
  • Urticaria pigmentosa rarely progresses to systemic mastocytosis in children but may do so more often in adults. (msdmanuals.com)
  • Numerous people with foundational mastocytosis foster urticaria pigmentosa, portrayed by raised areas of earthy skin that sting or tingle when contacted or when the temperature changes. (md-fm.com)
  • Changed or mutated forms of the c-kit gene may cause some types of mastocytosis, including systemic mastocytosis. (cancer.net)
  • Mastocytosis" Encyclopedia , https://encyclopedia.pub/entry/1647 (accessed December 06, 2023). (encyclopedia.pub)
  • WHO classified four major subtypes of extracutaneous systemic mastocytosis: (1) indolent systemic mastocytosis, (2) systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease (SM-AHNMD), (3) aggressive systemic mastocytosis, and (4) mast cell leukemia . (logicalimages.com)
  • Aggressive systemic mastocytosis, in which there is organ destruction from a mast cell infiltrate, is rare and should promote investigation for mast cell leukemia or other hematologic disorders such as myelodysplastic syndromes, myeloproliferative or myelodysplastic disorders, acute myeloid leukemia, and chronic myeloproliferative neoplasia. (logicalimages.com)
  • Mast cell leukemia is seen in two-thirds of patients with aggressive systemic mastocytosis and portends rapid progression that could potentially result in multi-organ failure. (logicalimages.com)
  • 16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neoplasm, and 16 had mast-cell leukemia. (uni-koeln.de)
  • Pleomorphic undifferentiated sarcoma , Langerhans cell histiocytosis and other pleomorphic tumours - for aggressive systemic mastocytosis . (librepathology.org)
  • Systemic mastocytosis (SM) can be further categorized into indolent SM, smouldering SM and aggressive SM. (ab-science.com)
  • SM with an associated hematologic neoplasm (SM-AHN), aggressive SM (ASM), and MC leukemia (MCL) are the three advanced forms, while the non-advanced form is broken down into BM mastocytosis (BMM), indolent SM (ISM), and smoldering SM (SSM). (md-fm.com)
  • If systemic mastocytosis is aggressive it can be life threatening. (homehealthbeauty.in)
  • In case of aggressive systemic mastocytosis chemotherapy is prescribed. (homehealthbeauty.in)
  • We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis. (qxmd.com)
  • Mast cell mediator-related symptoms responded in 71% of cases and 25% of aggressive systemic mastocytosis patients had a response in terms of B/C findings (borderline/cytoreduction needed). (qxmd.com)
  • A 52-year-old man received HLA-matched sibling allogeneic hematopoietic cell transplantation (alloHCT) for aggressive systemic mastocytosis (ASM) with KITD816V mutation. (ashpublications.org)
  • Foods are known triggers of anaphylaxis in people with mastocytosis. (healthline.com)
  • In a small study of people with mastocytosis, about 50% reported having fatigue. (healthline.com)
  • People with mastocytosis should always carry self-injecting syringe of epinephrine for prompt emergency treatment of anaphylactic or anaphylactoid reactions. (msdmanuals.com)
  • Because mast cells play a role in allergic reactions, the symptoms of mastocytosis often are similar to the symptoms of an allergic reaction. (wikipedia.org)
  • Generally, the signs and symptoms of mastocytosis are similar to an allergic reaction . (osmosis.org)
  • The symptoms of mastocytosis patients are related to the MC-derived mediators that exert local and distant effects. (unisa.it)
  • Although pediatric mastocytosis can spontaneously regress, it is a clonal disease most commonly associated with D816V and other activating c- kit mutations. (medscape.com)
  • Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. (umassmed.edu)
  • Mastocytosis is a heterogeneous group of rare diseases defined by abnormal accumulation of clonal mast cells (MC) in the skin, bone marrow and/or other visceral organs. (encyclopedia.pub)
  • Systemic mastocytosis (SM) is a clonal disease of mast cell progenitors from the bone marrow. (reumatologiaclinica.org)
  • Mastocytosis , or clonal mast cell disease, is a rare disorder that leads to increased numbers of incorrectly functioning mast cells . (osmosis.org)
  • In cases of suspicion of SM help can also be drawn from analysis of mutation in KIT(D816V) in peripheral blood using sensitive PCR-technology[citation needed] To set the diagnosis of systemic mastocytosis, certain criteria must be met. (wikipedia.org)
  • One major and 1 minor criterion or 3 minor diagnostic criteria are needed to establish a diagnosis of systemic mastocytosis. (medscape.com)
  • We present here consensus recommendations from a Nordic expert group for the diagnosis and general management of patients with mastocytosis. (ku.dk)
  • Mast cell activation syndrome - The more recently termed mast cell activation syndrome (MCAS) describes patients who have multiple mast cell mediator-induced symptoms that do not meet the WHO criteria (see Best Tests) for diagnosis of systemic mastocytosis when other underlying diseases have been excluded. (logicalimages.com)
  • If more than one tissue/organ is affected, the diagnosis of systemic mastocytosis (SM) should be made. (bmj.com)
  • Recently, a revised classification of mastocytosis has been published including clear cut criteria for diagnosis and subclassification. (bmj.com)
  • Recent advances in diagnosis and therapy in systemic mastocytosis. (qxmd.com)
  • NOTE: Mastocytosis Musings does not provide medical advice, diagnosis or treatment. (mastocytosismusings.org)
  • Butterfield, JH 2006, ' Systemic Mastocytosis: Clinical Manifestations and Differential Diagnosis ', Immunology and Allergy Clinics of North America , vol. 26, no. 3, pp. 487-513. (elsevierpure.com)
  • Butterfield, Joseph H. / Systemic Mastocytosis : Clinical Manifestations and Differential Diagnosis . (elsevierpure.com)
  • These two phase 2a studies enrolled a total of 46 patients in two sub-populations of patients suffering from indolent mastocytosis with handicap: one study in patients who did not carry the D816V mutation on the c-Kit gene and another in patients who did carry this mutation. (ab-science.com)
  • Localized mastocytosis (mastocytoma) is a single lesion (or sometimes 1-3 lesions), most often found in children. (cyberderm.net)
  • Mastocytosis is a disorder characterized by mast cell proliferation and accumulation within various organs, most commonly the skin. (medscape.com)
  • Mastocytosis is a disease characterized by the presence of purple-brown spots on the skin and the plane of internal organs as a result of the proliferation of mast cells, more often occurs in babies. (medprep.info)
  • Mastocytosis is a heterogeneous neoplasm characterized by accumulation of neoplastic mast cells in various organs. (qxmd.com)
  • People experiencing the burning hot variation might have a bigger number of organs influenced and more serious side effects than those experiencing sluggish mastocytosis. (md-fm.com)
  • Mastocytosis is health condition where the mast cells (certain type of immune cells) under the skin or in intestine, bones or other organs. (homehealthbeauty.in)
  • Mastocytosis can effect multiple organs and present variety of symptoms. (homehealthbeauty.in)
  • In systemic mastocytosis, the accelerated numbers of mast cells are determined in other organs, whether or no longer the clusters of mast cells are also present within the skin. (usa-good.com)
  • When you have systemic mastocytosis, excess mast cells increase on your skin, bone marrow, digestive tract or different body organs. (usa-good.com)
  • Mastocytosis is a disorder characterized by the abnormal proliferation and/or accumulation of mast cells in different organs. (unisa.it)
  • Fundamental mastocytosis is a myeloid neoplasm separated into six subcategories by the new grouping by WHO. (md-fm.com)
  • In diffuse type of mastocytosis and KIT anomaly a bone marrow aspiration is indicated. (cyberderm.net)
  • Mutations of the gene coding for the c-kit receptor (mutation KIT(D816V)), leading to constitutive signalling through the receptor is found in >90% of patients with systemic mastocytosis. (wikipedia.org)
  • Response rates were similar regardless of the subtype of advanced systemic mastocytosis, KIT mutation status, or exposure to previous therapy. (uni-koeln.de)
  • Some people have a genetic mutation that causes mastocytosis. (msdmanuals.com)
  • Systemic mastocytosis in particularly happens due to mutation. (homehealthbeauty.in)
  • More than 90% of patients with systemic mastocytosis have a gain-of-function mutation in codon 816 of the KIT receptor on mast cells (MCs). (unisa.it)
  • Mastocytosis skin lesions respond with an urticarial reaction spontaneously or after irritation (Darier's sign: wheal, erythema, itch). (cyberderm.net)
  • Mastocytosis, a type of mast cell disease, is a rare disorder affecting both children and adults caused by the accumulation of functionally defective mast cells (also called mastocytes) and CD34+ mast cell precursors. (wikipedia.org)
  • Systemic mastocytosis usually occurs in adults. (msdmanuals.com)
  • This photo shows reddish-brown spots on the back of a school-aged child with mastocytosis. (msdmanuals.com)
  • Dental treatment of a Seven-Year-Old Child with Mastocytosis. (bvsalud.org)
  • Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. (librepathology.org)
  • Mastocytosis is a rare disorder characterized by pathologic mast cell degranulation. (bvsalud.org)
  • Mastocytosis is now classified with the myeloproliferative neoplasms. (medscape.com)
  • BACKGROUND Advanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor prognosis and lack effective treatment options. (uni-koeln.de)
  • If mastocytosis affects only the skin, it may resolve without treatment, but if it affects other parts of the body, it cannot be cured. (msdmanuals.com)
  • Systemic mastocytosis is a rare disorder that affects the body's mast cells, leading to symptoms such as skin rash, abdominal pain, and anaphylaxis. (dantelabs.com)
  • Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? (bmj.com)
  • To clarify the nature (reactive or neoplastic) of lesional, perifocally aggregated lymphocytes in bone marrow infiltrates of systemic mastocytosis (SM), the histopathology of which can resemble malignant lymphoma with focal bone marrow involvement, particularly low grade malignant B cell lymphoma of lymphoplasmacytic immunocytoma subtype, which frequently exhibits increased mast cell (MC) numbers. (bmj.com)
  • 2011). "Systemic mastocytosis (SM) and associated malignant bone marrow histiocytosis - a hitherto undescribed form of SM-AHNMD. (librepathology.org)
  • Systemic mastocytosis requires the presence of at least one major and one minor criterion or three minor criteria in the bone marrow or other extracutaneous organ. (clinicaladvisor.com)
  • Mastocytosis (mast cell disease) is a relatively uncommon haematological tumour of bone marrow origin. (bmj.com)
  • Systemic mastocytosis (SM) was reported by Ellis in 1949 as an abnormal proliferation of mast cells infiltrating the skin, bone marrow, liver, spleen, alimentary canal and lymphatic nodes. (reumatologiaclinica.org)
  • 2] MPCM and TMEP can be a part of indolent systemic mastocytosis. (wikipedia.org)
  • [ 12 ] Impaired mast cell apoptosis has been postulated to be involved, as evidenced by up-regulation of the apoptosis-preventing protein BCL-2 demonstrated in patients with mastocytosis. (medscape.com)
  • Research from 2016 has shown that there are varied gene expressions in patients with mastocytosis and associated allergies. (medscape.com)
  • Other than patients being displeased (or even depressed) by their clinical appearance, I have never given the neuropsychiatric aspects of mastocytosis much (if any) thought. (aad.org)
  • According to Moura et al, approximately one-third of mastocytosis patients can display various disabling general and neuropsychological symptom, which may have a profound impact on their quality of life. (aad.org)
  • Brain "fog" characterizes patients with autism spectrum disorders (ASDs), celiac disease, chronic fatigue syndrome, fibromyalgia, mastocytosis, and postural tachycardia syndrome (POTS), as well as "minimal cognitive impairment," an early clinical presentation of Alzheimer's disease (AD), and other neuropsychiatric disorders. (aad.org)
  • 45% of the patients had a major response, which was defined as complete resolution of at least one type of mastocytosis-related organ damage. (uni-koeln.de)
  • CONCLUSIONS In this open-label study, midostaurin showed efficacy in patients with advanced systemic mastocytosis, including the highly fatal variant mast-cell leukemia. (uni-koeln.de)
  • Masitinib is developed in ISM and SSM, which are the most prevalent forms of mastocytosis, accounting for approximately 60% of patients. (ab-science.com)
  • Serum concentrations of VEGF-A, VEGF-C, VEGF-D, ANGPT1 and ANGPT2 were determined in 64 mastocytosis patients and 64 healthy controls. (unisa.it)
  • VEGF-A, ANGPT1, ANGPT2 and VEGF-C concentrations were higher in mastocytosis patients compared to controls. (unisa.it)
  • Serum concentrations of VEGFs and ANGPTs are altered in mastocytosis patients. (unisa.it)
  • Le pourcentage de CD44 dans les lymphocytes T périphériques était significativement plus élevé chez les patients que chez les témoins, comme détecté par la cytométrie en flux. (who.int)
  • En outre, il y avait une aug- mentation significative de la forme soluble du c-kit dans le sérum des patients atteints de pemphigus vulgaire actif par rapport aux témoins. (who.int)
  • The article references a review by the Spanish Network on Mastocytosis [ 6 ] that followed 45 pregnant patients with the disease and found that "in most cases mastocytosis -related symptoms remained unchanged throughout pregnancy and after delivery compared to the pregestational clinical profile. (medscape.com)
  • Inappropriate, recurrent mast cell activation (MCA) and secretion MC-derived mediators plays an essential role in many human diseases: allergy, asthma, allergic rhinitis, urticaria, anaphylaxis, atopic dermatitis, mastocytosis and mast cell activation syndrome (MCAS) [ 5 ] . (encyclopedia.pub)
  • People affected by mastocytosis are susceptible to a variety of symptoms, including itching, hives, and anaphylactic shock, caused by the release of histamine and other pro-inflammatory substances from mast cells. (wikipedia.org)
  • If the base level of s-tryptase is elevated, this implies that the mastocytosis can be systemic. (wikipedia.org)
  • Mastocytosis is a rare disorder where mast cells are abnormally high in number (a type of white blood cell) and activated throughout the body . (osmosis.org)
  • [ 3 ] Distinct polymorphisms correlate with mastocytosis subtypes. (medscape.com)
  • Mastocytosis is a heterogeneous group of diseases defined by an increased number and accumulation of mast cells, and often also by signs and symptoms of mast cell activation. (ku.dk)
  • Mastocytosis is a disease characterized by an abnormal increase in mast cells. (nih.gov)
  • Mastocytosis is the abnormal growth of cells from the immune system in your body. (familydoctor.org)
  • Mastocytosis is an uncommon abnormal accumulation of mast cells in the skin and sometimes in various other parts of the body. (msdmanuals.com)
  • Systemic mastocytosis is caused by mutations in genes involved in the regulation of mast cells, and this panel tests for genetic variants that are known to affect these processes. (dantelabs.com)
  • Mutations in KIT that preserve the transfer ON are the motive of mastocytosis. (usa-good.com)
  • Mastocytosis is variable in respect to the organ systems involved, clinical manifestations, and association with hematologic diseases. (nih.gov)
  • Mastocytosis is a diverse group of disorders characterised by the expansion and accumulation of mast cells in one or more organ systems. (dermnetnz.org)
  • Mastocytosis can lead to organ failure as well as systemic symptoms that can be disabling, with considerable deterioration in quality of life. (qxmd.com)
  • Mastocytosis is a sickness in which odd mast cells are accelerated in a single or extra organ. (usa-good.com)
  • Anaphylaxis, a severe allergic reaction, will occur in nearly half of those diagnosed with systemic mastocytosis. (md-fm.com)
  • This panel is designed for individuals with a family history of systemic mastocytosis or individuals with symptoms of the condition, such as skin rash, abdominal pain, and anaphylaxis. (dantelabs.com)
  • You cannot prevent mastocytosis, but you can avoid severe allergic reactions by avoiding situations, foods and medications that can trigger macrocytosis. (homehealthbeauty.in)
  • [ 14 ] IL-6 levels have been shown to be elevated and correlated with disease severity, indicating interleukin 6 is involved in the pathophysiology of mastocytosis. (medscape.com)
  • The heterogeneity of the disease patterns in mastocytosis strongly suggests that more than one biologic lesion may occur in the developmental sequence that leads to placement of mature mast cells in tissues. (nih.gov)
  • Systemic mastocytosis is a less common myeloproliferative variant composed of a heterogeneous disease compilation. (logicalimages.com)
  • Systemic mastocytosis with a chronic myeloproliferative neoplasia (SM-AHNMD) has a course and prognosis determined by efficacy of management of the underlying disease. (logicalimages.com)
  • This downloadable slide set presents an expert discussion detailing the limitations of conventional treatments for indolent systemic mastocytosis and the role of disease-modifying therapy in improving patient outcomes. (clinicaloptions.com)
  • Systemic mastocytosis is a life-threatening disease in which mast cell mediator release can lead to general symptoms. (authorea.com)
  • Mastocytosis, mast cell disease. (cyberderm.net)
  • Mastocytosis is a rare disease characterized by proliferation and accumulation of mast cells in various tissues, causing a wide variety of clinical symptoms. (ab-science.com)
  • Mastocytosis can occur at any age, although some types are more common in particular age groups. (dermnetnz.org)